Tonghua Dongbao Pharmaceut (600867.SS) traded flat 0 % during a 24 hours period ending at 05:10 PM Central Europe on Tuesday 27th. One Tonghua Dongbao Pharmaceut stock can currently be bought for about CNY 7.66 on popular exchanges. Current supply of Tonghua Dongbao Pharmaceut stocks is 2 bn. Tonghua Dongbao Pharmaceut has a current market capitalization of CNY 15.2 bn and approximately CNY 123.4 mn worth of Tonghua Dongbao Pharmaceut was traded on exchanges in the last 24 hours. Since last month end, Tonghua Dongbao Pharmaceut has traded 1.68 % up. Simple moving average of last 200 days is at CNY 8.02. The highest price of past 52 weeks was recorded at CNY 10.67 on 04/15/2026. 52 weeks low was at CNY 7.16 on 06/22/2026.
Here is how related stocks have performed in the past 24 hours:
Shanxi Securities (002500.SZ) traded flat 0 % and now trades at CNY 5.01. Current market capitalisation for Shanxi Securities is CNY 18.2 bn. Shanxi Securities has a current price to earnings ratio of 18.21. Shanxi Securities Co. Ltd. reported a strong rebound in its third‑quarter operating results, with revenue and net profit both showing significant year‑on‑year increases. Management attributed the upside to higher sales of coal and urea, driven by price rises and greater volumes. Cash‑flow generation improved markedly, reflecting the stronger top line. Analysts from regional securities firms highlighted the company’s integrated coal‑and‑chemical chain as a key strength, noting that the firm’s profitability has moved from a loss‑making position to a robustly profitable one. The share price experienced a modest decline at open before recovering later in the session, reflecting market volatility rather than a fundamental change in outlook. Overall, the company’s recent performance has reinforced confidence in its operational turnaround and the resilience of its core business.
Sichuan Hebang Biotechnol (603077.SS) traded flat 0 % and now trades at CNY 2.05. Current market capitalisation for Sichuan Hebang Biotechnol is CNY 18.3 bn. Sichuan Hebang Biotechnology released its financial results for the quarter ending 30 September 2026 at an all‑three‑month finance conference. The company reported earnings per share that were essentially unchanged from the same period a year earlier, while revenue fell by about 19 percent, dropping to roughly 1.6 billion yuan from 2.0 billion yuan in the prior year. In the same week, the firm disclosed its latest quarterly report, noting that seven institutional investors now hold roughly a third of its shares. The list of holders includes local investment groups, state‑owned enterprises, and several fund managers. This institutional ownership represents a modest decline from the previous quarter. The data provide a snapshot of the company’s recent financial performance and shareholder composition.
Guangzhou Zhujiang Brewery (002461.SZ) traded flat 0 % and now trades at CNY 8.09. Current market capitalisation for Guangzhou Zhujiang Brewery is CNY 18.3 bn. Guangzhou Zhujiang Brewery has a current price to earnings ratio of 19.75. Guangzhou Zhujiang Brewery reported a mixed first three‑quarter performance. Revenue and profit reached record highs for the year, but the third quarter saw a slight decline in both metrics, reflecting a gradual slowdown in growth compared with previous years. The company’s flagship mid‑to‑high‑end product, the 97 Pure Draft, has driven a price‑premium strategy, yet rising raw‑material and packaging costs, along with higher tax rates, have begun to erode margins. Sales in on‑premise venues, particularly night‑life, have weakened, though online and supermarket channels have shown robust growth. The firm is expanding its premium lineup and engaging in broader marketing initiatives to support its “Beer+” strategy. Despite these efforts, the stock has weakened, and market sentiment remains cautious regarding the sustainability of its pricing gains.
Joincare Pharmaceutical Gr (600380.SS) traded flat 0 % and now trades at CNY 9.85. Joincare Pharmaceutical Gr has a market capitalisation of CNY 18.1 bn. Current price/earnings ratio for Joincare Pharmaceutical Gr is 14.87. Health Care Group Co., Ltd. reported its third‑quarter performance for 2026, noting a decline in operating revenue and net profit compared with the same period last year. The company highlighted a reduction in cash flows from operating activities and a slight contraction in total assets, while shareholders’ equity also fell. Management explained that the downturn was largely due to lower sales and a decrease in accounts receivable, offset partially by gains from investments and an increase in goodwill and use‑right assets following a subsidiary acquisition. The firm announced a shareholder return plan for the next three years, aiming to distribute a substantial portion of future profits to shareholders. Additionally, it issued a revised corporate charter and outlined a profit‑distribution proposal for the quarter. These disclosures underscore the company’s focus on restructuring and returning value to investors while navigating a challenging operating environment.
Chengdu Kanghong Pharmaceu (002773.SZ) traded flat 0 % and now trades at CNY 18.89. Current market capitalisation for Chengdu Kanghong Pharmaceu is CNY 18.3 bn. Current price/earnings ratio for Chengdu Kanghong Pharmaceu is 14.75. On October 27, the Shanghai Composite, Shenzhen Component, and ChiNext indices all declined modestly, with the ChiNext index dropping the most. Market activity reached nearly 870 billion yuan in total trade volume. Several sector themes moved in opposite directions: the reducer concept gained strength, with key constituents posting notable gains; the F5G concept remained active, while the duty‑free store theme also showed upward momentum. In contrast, the electronic ID theme weakened, and the Alzheimer’s disease theme experienced a pullback across several pharmaceutical names. The market overall featured a larger number of stocks declining than rising, reflecting a mixed sentiment among investors.
About Tonghua Dongbao Pharmaceut
Tonghua Dongbao Pharmaceutical Co., Ltd. is a health care company based in Tonghua, China that specializes in manufacturing and marketing Western medicines, Chinese medicines, biological products, and plastic building materials.